Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.3% Higher – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 0.3% on Wednesday . The stock traded as high as $6.72 and last traded at $6.49. 6,993,546 shares changed hands during trading, a decline of 73% from the average session volume of 25,691,047 shares. The stock had previously closed at $6.47.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday. Finally, KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Up 1.5 %

The firm has a market cap of $2.57 billion, a P/E ratio of -4.28 and a beta of 0.86. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $7.69 and a 200-day moving average price of $7.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The firm’s revenue was down 57.8% on a year-over-year basis. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Integrated Advisors Network LLC increased its holdings in shares of Recursion Pharmaceuticals by 36.8% in the 4th quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company’s stock valued at $119,000 after acquiring an additional 4,731 shares during the period. GF Fund Management CO. LTD. bought a new stake in Recursion Pharmaceuticals during the fourth quarter valued at about $54,000. CSS LLC IL bought a new position in Recursion Pharmaceuticals in the fourth quarter worth about $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Recursion Pharmaceuticals by 5.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company’s stock valued at $15,272,000 after buying an additional 118,428 shares during the last quarter. Finally, Vident Advisory LLC bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $80,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.